hello you semaglutide SkinnyRx certified physician support. Hello You | Weight Loss

For an unlicensed investigational compound such as retatrutide, no such validated stability data exist

Also published in the New England Journal of Medicine in 2022, the SURMOUNT-1 trial demonstrated that tirzepatide at the 15 mg dose produced an average weight loss of 22.5% of body weight over 72 weeks approaching results typically seen with bariatric surgery (Jastreboff et al., 2022, PMID: 35658024)

Legitimizing these peptides for compounding doesn't require nearly the same degree of evidence as FDA drug approval, but the agency still has a "responsibility to ensure that there's some level of safety before they become widely available," explains Bernstein

W., Faurschou, A